| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 5566 | trifluoperazine | ADCY1, ADCY3, ADCY4, ADCY6, ADCY8, ADCY9, ADRA1A, ANXA10, ANXA13, ANXA2, ANXA3, ANXA5, ANXA6, CALM1, CALY, DRD2, DRD4, DRD5, F2, FDPS, GRK7, LTB4R, MYH1, MYH2, MYH4, MYH7B, MYL1, MYL12A, MYL2, MYL7, MYL9, MYLK, MYO15A, MYO18B, MYO1C, MYO1D, MYO1E, MYO3A, MYO3B, MYO5B, MYO5C, NDUFAF3, NDUFS5, S100A4, SLC1A5, SLC5A11, SLC7A5, TNNC1, TNNI3, TNNT2 | Antipsychotic Agents, Antiemetics, Alcoholic Intoxication, Chronic, Bipolar Disorder, Catatonia, Hallucinations, Psychotic Disorders, Schizophrenia, Paranoid Schizophrenia, Brain Injuries, Mental deficiency, Alcoholism, Alcohol abuse, Bipolar disorder, Bipolar I disorder, Hallucination, Psychotic disorder, Schizophrenia, paranoid type, Brain injury |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | GABRA1 (P14867) | 0.0653 | 0 | - |
| trifluoperazine | PLA2G1B (P04054) | 0.0652 | 0 | - |
| trifluoperazine | SLC32A1 (Q9H598) | 0.0651 | 0 | - |
| trifluoperazine | SLC19A3 (Q9BZV2) | 0.065 | 0 | - |
| trifluoperazine | COQ6 (Q9Y2Z9) | 0.0649 | 0 | - |
| trifluoperazine | TXNRD1 (Q16881) | 0.0648 | 0 | - |
| trifluoperazine | CYP17A1 (P05093) | 0.0647 | 0 | - |
| trifluoperazine | PLD2 (O14939) | 0.0647 | 0 | - |
| trifluoperazine | AADAC (P22760) | 0.0647 | 0 | - |
| trifluoperazine | GPR18 (Q14330) | 0.0646 | 0 | - |
| trifluoperazine | O15770 | 0.0645 | 0 | - |
| trifluoperazine | FDX1 (P10109) | 0.0643 | 0 | - |
| trifluoperazine | P32211 | 0.0643 | 0 | - |
| trifluoperazine | IFNG (P01579) | 0.064 | 0 | - |
| trifluoperazine | CA14 (Q9ULX7) | 0.0639 | 0 | - |
| trifluoperazine | NDUFC1 (O43677) | 0.0637 | 0 | - |
| trifluoperazine | P30994 | 0.0635 | 0 | - |
| trifluoperazine | P12758 | 0.0634 | 0 | - |
| trifluoperazine | TNFSF13B (Q9Y275) | 0.0634 | 0 | - |
| trifluoperazine | HPGDS (O60760) | 0.0632 | 0 | - |
| trifluoperazine | KEAP1 (Q14145) | 0.063 | 0 | - |
| trifluoperazine | IL36G (Q9NZH8) | 0.0629 | 0 | - |
| trifluoperazine | Q9H0P7 | 0.0627 | 0 | - |
| trifluoperazine | CATSPER2 (Q96P56) | 0.0627 | 0 | - |
| trifluoperazine | TUBD1 (Q9UJT1) | 0.0623 | 0 | - |
| trifluoperazine | GRM7 (Q14831) | 0.0623 | 0 | - |
| trifluoperazine | CHRNA4 (P43681) | 0.0623 | 0 | - |
| trifluoperazine | CA13 (Q8N1Q1) | 0.0616 | 0 | - |
| trifluoperazine | SLC25A4 (P12235) | 0.0615 | 0 | - |
| trifluoperazine | PSMD8 (P48556) | 0.0615 | 0 | - |
| trifluoperazine | ARL14EP (Q8N8R7) | 0.0614 | 0 | - |
| trifluoperazine | CACNG6 (Q9BXT2) | 0.0613 | 0 | - |
| trifluoperazine | CACNG5 (Q9UF02) | 0.061 | 0 | - |
| trifluoperazine | AMER3 (Q8N944) | 0.0608 | 0 | - |
| trifluoperazine | IL3 (P08700) | 0.0607 | 0 | - |
| trifluoperazine | PRSS3 (P35030) | 0.0606 | 0 | - |
| trifluoperazine | EIF2AK4 (Q9P2K8) | 0.0604 | 0 | - |
| trifluoperazine | SLC1A3 (P43003) | 0.0604 | 0 | - |
| trifluoperazine | ESRRA (P11474) | 0.0603 | 0 | - |
| trifluoperazine | Q9Z7H2 | 0.06 | 0 | - |
| trifluoperazine | ADRA2B (P18089) | 0.0599 | 0 | - |
| trifluoperazine | TYMS (P04818) | 0.0598 | 0 | - |
| trifluoperazine | STK33 (Q9BYT3) | 0.0598 | 0 | - |
| trifluoperazine | P21588 | 0.0595 | 0 | - |
| trifluoperazine | CYP4F22 (Q6NT55) | 0.0593 | 0 | - |
| trifluoperazine | O09800 | 0.0591 | 0 | - |
| trifluoperazine | P09482 | 0.0589 | 0 | - |
| trifluoperazine | SAP30 (O75446) | 0.0589 | 0 | - |
| trifluoperazine | NTRK1 (P04629) | 0.0588 | 0 | - |
| trifluoperazine | P42866 | 0.0585 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| trifluoperazine | GO:0006281 DNA repair | 1 | 1 |
| trifluoperazine | GO:0031570 DNA integrity checkpoint | 1 | 1 |
| trifluoperazine | GO:0007049 cell cycle | 0.875 | 1 |
| trifluoperazine | GO:0008283 cell population proliferation (viability) | 0.7 | 1 |
| trifluoperazine | GO:0071456 cellular response to hypoxia | 0.3333 | 0 |
| trifluoperazine | GO:0001525 angiogenesis | 0.2857 | 0 |
| trifluoperazine | GO:0008283 cell population proliferation | 0.25 | 0 |
| trifluoperazine | GO:0006954 inflammatory response | 0.2 | 0 |
| trifluoperazine | GO:0008219 cell death | 0.0625 | 0 |
| trifluoperazine | GO:0006096 glycolytic process | 0 | 0 |
| trifluoperazine | GO:0016477 cell migration | 0 | 0 |
| trifluoperazine | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| trifluoperazine | GO:0002418 immune response to tumor cell | 0 | 0 |
| trifluoperazine | GO:0010833 telomere maintenance via telomere lengthening | 0 | 0 |
| trifluoperazine | GO:0001570 vasculogenesis | 0 | 0 |
| trifluoperazine | GO:0007155 cell adhesion | 0 | 0 |
| trifluoperazine | GO:0016049 cell growth | 0 | 0 |
| trifluoperazine | GO:0006915 apoptotic process | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | Cancer(general) | 0.6236 | 0 | - |